Compare HLI & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HLI | KRYS |
|---|---|---|
| Founded | 1972 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 9.6B |
| IPO Year | 2015 | 2017 |
| Metric | HLI | KRYS |
|---|---|---|
| Price | $136.55 | $351.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 11 |
| Target Price | $194.29 | ★ $297.60 |
| AVG Volume (30 Days) | ★ 640.4K | 200.3K |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.54% | N/A |
| EPS Growth | 6.87 | ★ 128.00 |
| EPS | 1.15 | ★ 3.62 |
| Revenue | ★ $2,617,516,000.00 | $389,130,000.00 |
| Revenue This Year | $13.77 | $38.74 |
| Revenue Next Year | $12.10 | $32.53 |
| P/E Ratio | $117.63 | ★ $96.16 |
| Revenue Growth | 9.55 | ★ 33.94 |
| 52 Week Low | $112.83 | $145.46 |
| 52 Week High | $211.78 | $382.54 |
| Indicator | HLI | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 58.60 | 48.23 |
| Support Level | $133.57 | $289.36 |
| Resistance Level | $144.92 | $382.33 |
| Average True Range (ATR) | 3.65 | 11.24 |
| MACD | 0.94 | -0.73 |
| Stochastic Oscillator | 67.51 | 28.36 |
Houlihan Lokey Inc is an investment bank with expertise in mergers and acquisitions, capital markets, financial restructuring, valuation, and strategic consulting. The firm serves corporations, institutions, and governments world-wide with offices in the United States, Europe, and the Asia-Pacific region. The company operates in three segments. In the Corporate Finance business segment, it provides M&A and capital markets advisory services. Through the Financial Restructuring business segment, the company advises on some of the complex restructurings around the world. The Financial and Valuation Advisory Services business segment provides valuation and financial opinion, and financial and strategic consulting practices in the United States.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.